Therapeutic approaches and epidemiology of Crohn's Disease in Brazil: a scoping review
DOI:
https://doi.org/10.17765/2176-9206.2026v19e13160Keywords:
Crohn’s disease, Epidemiology, Scoping review, Therapeutic approachesAbstract
This paper addresses the therapeutic strategies and epidemiology of Crohn’s Disease (CD) in the Brazilian context, covering the period from January 2019 to May 2024. A scoping review was conducted using databases such as PubMed, Scopus, SciELO, Cochrane Library, Web of Science, and the Virtual Health Library (VHL). In addition, incidence and prevalence rates of CD in Brazil were examined using data from the Unified Health System (SUS). This study highlighted that CD represents a challenge for the Brazilian healthcare system, with a substantial number of patients requiring frequent therapeutic interventions. This approach focuses on biological medications, such as anti-TNF-? agents. The epidemiological analysis also emphasized the importance of closely monitoring CD incidence and prevalence rates in Brazil, especially considering the growing number of diagnosed cases.
Downloads
References
1. Roda G, Longhi EV. Crohn’s disease. In: Managing psychosexual consequences in chronic diseases [Internet]. Cham: Springer International Publishing; 2023. p. 237–49. Available from: http://dx.doi.org/10.1007/978-3-031-31307-3_19
2. Dolinger M, Torres J, Vermeire S. Crohn’s disease. Lancet [Internet]. 2024 Mar 1;403(10432):S0140-6736(23)025862. Available from: https://doi.org/10.1016/S0140-6736(23)02586-2
3. Saez A, Herrero-Fernandez B, Gomez-Bris R, Sánchez-Martinez H, Gonzalez-Granado JM. Pathophysiology of inflammatory bowel disease: innate immune system. Int J Mol Sci [Internet]. 2023 Jan 12;24(2):1526. Available from: http://doi.org/10.3390/ijms24021526
4. Flynn S, Eisenstein S. Inflammatory bowel disease presentation and diagnosis. Surg Clin North Am [Internet]. 2019 Dec;99(6):1051–62. Available from: https://doi.org/10.1016/j.suc.2019.08.001
5. Ramos GP, Papadakis KA. Mechanisms of disease: inflammatory bowel diseases. Mayo Clin Proc [Internet]. 2019 Jan;94(1):155–65. Available from: https://doi.org/10.1016/j.mayocp.2018.09.013
6. Buie MJ, Quan J, Windsor JW, Coward S, Hansen TM, King JA, et al. Global hospitalization trends for Crohn’s disease and ulcerative colitis in the 21st century: a systematic review with temporal analyses. Clin Gastroenterol Hepatol [Internet]. 2023 Jul 18;0(0). Available from: https://doi.org/10.1016/j.cgh.2022.06.030
7. The global, regional, and national burden of inflammatory bowel disease in 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017 [Internet]. Institute for Health Metrics and Evaluation; 2017. Available from: https://doi.org/10.1016/S2468-1253(19)30333-4
8. Gergely M, Deepak P. Tools for the diagnosis and management of Crohn’s disease. Gastroenterol Clin North Am [Internet]. 2022 Apr;51(2):213–39. Available from: https://doi.org/10.1016/j.gtc.2021.12.003
9. Associação Brasileira de Colite Ulcerativa e Doença de Crohn (ABCD). Jornada do paciente com doença inflamatória intestinal [Internet]. 2017 Sep [cited 2024 May 30]. Available from: https://abcd.org.br/wp-content/uploads/2018/01/JORNADA_DO_PACIENTE_COMPLETA.pdf
10. Ng SC, Shi HY, Hamidi N, Underwood FE, Tang W, Benchimol EI, et al. Early course of inflammatory bowel disease in a population-based inception cohort study from 8 countries in Asia and Australia. Gastroenterology [Internet]. 2016 Jan;150(1):86-95.e3. Available from: https://doi.org/10.1053/j.gastro.2015.09.005.
11. Ananthakrishnan AN. Epidemiology and risk factors for IBD. Nat Rev Gastroenterol Hepatol [Internet]. 2015;12(4):205–17. Available from: http://doi.org/10.1038/nrgastro.2015.34
12. Barberio B, Gracie DJ, Black CJ, Ford AC. Efficacy of biological therapies and small molecules in induction and maintenance of remission in luminal Crohn’s disease: systematic review and network meta-analysis. Gut [Internet]. 2023;72(2):264–74. Available from: https://doi.org/10.1136/gutjnl-2022-328052
13. Shehada M, McMahon LE. Recurrent Crohn's disease. Semin Pediatr Surg [Internet]. 2024 Apr;33(2):151403. Available from: https://doi.org/10.1016/j.sempedsurg.2024.151403
14. Yamamoto-Furusho JK, Parra-Holguín NN. Emerging therapeutic options in inflammatory bowel disease. World J Gastroenterol [Internet]. 2021;27(48):8242. Available from: https://doi.org/10.3748/wjg.v27.i48.8242
15. Pinheiro BR, Camargos GLN, Queiroz RT, Fonseca ÉF. Perfil epidemiológico das internações relativas à Doença de Crohn e Colite Ulcerativa no estado de Minas Gerais. Res Soc Dev [Internet]. 2024;13(12):e191131247826. Available from: http://dx.doi.org/10.33448/rsd-v13i12.47826
16. Crespi M, Dulbecco P, De Ceglie A, Conio M. Strictures in Crohn’s disease: from pathophysiology to treatment. Dig Dis Sci [Internet]. 2020;65:1904–16. Available from: https://doi.org/10.1007/s10620-020-06227-0
17. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ [Internet]. 2021 Mar 29;372:n71. Available from: https://doi.org/10.1136/bmj.n71
18. Costa GA, Carvalho GS, Pereira LC, Gesteira S, Brasil CA. Epidemiological profile of patients with Crohn’s disease and ulcerative colitis in the last 6 years. J Health Sci [Internet]. 2022 Mar 22 [cited 2024 Mar 21];24(1):63–6. Available from: https://doi.org/10.17921/2447-8938.2022v24n1p63-66
19. Kotze PG, Underwood FE, Damião AOMC, Ferraz JGP, Saad-Hossne R, Toro M, et al. Progression of inflammatory bowel diseases throughout Latin America and the Caribbean: a systematic review. Clin Gastroenterol Hepatol [Internet]. 2020 Feb 1;18(2):304–12. Available from: https://doi.org/10.1016/j.cgh.2019.06.030
20. Lima Martins A, Volpato RA, Zago-Gomes M da P. The prevalence and phenotype in Brazilian patients with inflammatory bowel disease. BMC Gastroenterol [Internet]. 2018 Jun 18;18(1). Available from: https://doi.org/10.1186/s12876-018-0822-y
21. Martins KR, Araújo JM de, Cruz ÁC, Luiz-Ferreira A. Epidemiologic aspects of inflammatory bowel disease in the western region of Minas Gerais state. Arq Gastroenterol [Internet]. 2021 Sep;58(3):377–83. Available from: https://doi.org/10.1590/S0004-2803.202100000-63
22. Ng SC, Shi HY, Hamidi N, Underwood FE, Tang W, Benchimol EI, et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. Lancet. 2017 Dec;390(10114):2769–78. Available from: https://doi.org/10.1016/S0140-6736(17)32448-0
23. Quaresma AB, Kaplan GG, Kotze PG. The globalization of inflammatory bowel disease. Curr Opin Gastroenterol [Internet]. 2019 Apr;35(00):1. Available from: https://doi.org/10.1097/MOG.0000000000000534
24. Renuzza SSS, Vieira ER, Cornel CA, Lima MN, Ramos Junior O. Incidence, prevalence, and epidemiological characteristics of inflammatory bowel diseases in the state of Paraná in southern Brazil. Arq Gastroenterol [Internet]. 2022 Sep 9;59(03):327–33. Available from: https://www.scielo.br/j/ag/a/r7YwphBjqfY45K7MVmmbWFJ/?lang=en
25. Sturm A, Maaser C, Calabrese E, Annese V, Fiorino G, Kucharzik T, et al. ECCO-ESGAR guideline for diagnostic assessment in IBD part 2: IBD scores and general principles and technical aspects. J Crohns Colitis [Internet]. 2018 Aug 24;13(3):273–84. Available from: https://doi.org/10.1093/ecco-jcc/jjy114
26. Pires Martins VC, Ferreira JV, Pavan Vaz J, Suzuki Silva G, Vilela de Almeida JL. Abordagens cirúrgicas na doença de Crohn: resultados e complicações. Braz J Implantol Health Sci [Internet]. 2023 Nov 17 [cited 2025 Mar 26];5(5):3251–62. Available from: https://doi.org/10.36557/2674-8169.2023v5n5p3251-3262
27. Fucilini LMP, Genaro LM, Sousa DC e, Coy CSR, Leal RF, Ayrizono M de LS. Epidemiological profile and clinical characteristics of inflammatory bowel diseases in a Brazilian referral center. Arq Gastroenterol [Internet]. 2021 Oct;58(4):483–90. Available from: https://doi.org/10.1590/S0004-2803.202100000-87
28. Ministério da Saúde. Informações de Saúde (TABNET) – DATASUS [Internet]. Saude.gov.br. 2024 [cited 2024 May 29]. Available from: https://datasus.saude.gov.br/informacoes-de-saude-tabnet/
29. Sacramento AP, Meneses A de FP, Almeida AO, Portugal CM, Barros MS de R. Relatório para sociedade: informações sobre recomendações de incorporação de medicamentos e outras tecnologias no SUS – Calprotectina fecal no monitoramento de pacientes com doença de Crohn envolvendo o cólon [Internet]. Bonan LFS, editor. Secretaria de Ciência, Tecnologia e Inovação e do Complexo Econômico-Industrial da Saúde – SECTICS: Ministério da Saúde; 2023 [cited 2024 Jun 2]. Available from: https://www.gov.br/conitec/pt-br/midias/consultas/relatorios/2023/sociedade/20231228_resoc_440_calprotectina_doenca-de-crohn.pdf
30. Farraye FA, Melmed GY, Lichtenstein GR, Kane SV. ACG clinical guideline: preventive care in inflammatory bowel disease. Am J Gastroenterol. 2017 Feb;112(2):241–58. Available from: https://doi:10.1038/ajg.2016.537
31. Cushing K, Higgins PDR. Management of Crohn disease. JAMA [Internet]. 2021 Jan 5;325(1):69. Available from: https://doi.org/10.1001/jama.2020.18936
32. Ministério da Saúde. Secretaria de Atenção à Saúde. Portaria Conjunta nº 14, de 28 de novembro de 2017 [Internet]. Protocolo clínico e diretrizes terapêuticas da doença de Crohn. Comissão Nacional de Incorporação de Tecnologias no Sistema Único de Saúde – CONITEC: Ministério da Saúde; 2017 Nov 28 [cited 2024 May 29]. Available from: https://www.gov.br/conitec/pt-br/midias/protocolos/portaria_conjunta_14_pcdt_doenca_de_crohn_28_11_2017-1.pdf
33. Quaresma AB, Damiao AOMC, Coy CSR, Magro DO, Hino AAF, Valverde DA, et al. Temporal trends in the epidemiology of inflammatory bowel diseases in the public healthcare system in Brazil: A large population-based study. Lancet Reg Health Am [Internet]. 2022 Sep;13(100298):100298. Available from: https://doi.org/10.1016/j.lana.2022.100298
34. Picon PD, Mainka F, Oliota AFR, Fachi M, Krug BC, Mattos BA de, et al. Relatório de Recomendação – Medicamento nº 864. Ustequinumabe para o tratamento de pacientes com doença de Crohn ativa moderada a grave [Internet]. Comissão Nacional de Incorporação de Tecnologias no Sistema Único de Saúde – CONITEC: Ministério da Saúde; 2023 Dec. Available from: https://www.gov.br/conitec/pt-br/midias/relatorios/2024/20240123_relatorio_864_ustequinumabe.pdf
35. Lomazi EA, Oba J, Rodrigues M, Marmo MC da R, Sandy NS, Sdepanian VL, et al. Brazilian consensus on the management of inflammatory bowel diseases in pediatric patients: A consensus of the Brazilian Organization for Crohn’s Disease and Colitis (GEDIIB). Arq Gastroenterol [Internet]. 2023 Mar 24;59(01):85–124. Available from: https://www.scielo.br/j/ag/a/KL5Vpy5S8QWgVtfH73vdG7h/
36. Tinsley M, Grande C, Olson K, Plato L, Jacobs I. Potential of biosimilars to increase access to biologics: Considerations for advanced practice providers in oncology. J Adv Pract Oncol [Internet]. 2018 Dec 1 [cited 2024 Aug 12];9(7). Available from: https://jadpro.com/issues/volume-9-number-7-novdec-2018/potential-of-biosimilars-to-increase-access-to-biologics-considerations-for-advanced-practice-providers-in-oncology/
37. Agência Nacional de Vigilância Sanitária (ANVISA). Resolução da Diretoria Colegiada – RDC nº 31, de 29 de maio de 2014. Dispõe sobre o procedimento simplificado de solicitações de registro, pós-registro e renovação de registro de medicamentos genéricos, similares, específicos, dinamizados, fitoterápicos e biológicos e dá outras providências [Internet]. Diário Oficial da União; 2014 May. Available from: https://bvsms.saude.gov.br/bvs/saudelegis/anvisa/2014/rdc0031_29_05_2014.pdf
38. Pimenta MV, Monteiro G. The production of biopharmaceuticals in Brazil: current issues. Braz J Pharm Sci [Internet]. 2019 [cited 2024 May 4];55(e17823). Available from: https://doi.org/10.1590/s2175-97902019000217823
39. Privato MB, Martinez LL, Schmidt C. Biofármacos no Brasil: uma revisão do processo de regulamentação. Arq Med Hosp Fac Cienc Med Santa Casa São Paulo [Internet]. 2020 May 14;65(1):1–14. Available from: https://arquivosmedicos.fcmsantacasasp.edu.br/index.php/AMSCSP/article/view/602/866
40. Ungaro RC, Aggarwal S, Topaloglu O, Lee WJ, Clark R, Colombel JF. Systematic review and meta-analysis: efficacy and safety of early biologic treatment in adult and paediatric patients with Crohn’s disease. Aliment Pharmacol Ther. 2020 Mar 23;51(9):831–42. Available from: https://doi.org/10.1111/apt.15685
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Saúde e Pesquisa
This work is licensed under a Creative Commons Attribution 4.0 International License.
A submissão de originais para a revista Saúde e Pesquisa implica na transferência da Carta Concessão de Direitos Autorais, pelos autores, dos direitos de publicação digital para a revista após serem informados do aceite de publicação.A Secretaria Editorial irá fornecer da um modelo de Carta de Concessão de Direitos Autorais, indicando o cumprimento integral de princípios éticos e legislação específica. Os direitos autorais dos artigos publicados nesta revista são de direito do autor, com direitos da revista sobre a primeira publicação. Os autores somente poderão utilizar os mesmos resultados em outras publicações, indicando claramente a revista Saúde e Pesquisa como o meio da publicação original. Em virtude de tratar-se de um periódico de acesso aberto, é permitido o uso gratuito dos artigos, principalmente em aplicações educacionais e científicas, desde que citada a fonte. A Saúde e Pesquisa adota a licença Creative Commons Attribution 4.0 International.
A revista se reserva o direito de efetuar, nos originais, alterações de ordem normativa, ortográfica e gramatical, com vistas a manter o padrão culto da língua e a credibilidade do veículo. Respeitará, no entanto, o estilo de escrever dos autores. Alterações, correções ou sugestões de ordem conceitual serão encaminhadas aos autores, quando necessário. Nesses casos, os artigos, depois de adequados, deverão ser submetidos a nova apreciação. As opiniões emitidas pelos autores dos artigos são de sua exclusiva responsabilidade.
